PDF
(Download)
|
- Luteolin
- Quercetin
- Autism Spectrum Disorders
|
Date:
06-30-2014 | HC# 021453-499
|
Re: Luteolin and Quercetin Formulation Improves Adaptive Functioning and Behavior in Children with Autism Spectrum Disorders
Taliou
A, Zintzaras E, Lykouras L, Francis K. An open-label pilot study of a
formulation containing the anti-inflammatory flavonoid luteolin and its effects
on behavior in children with autism spectrum disorders. Clin Ther. 2013;35(5):592-602.
Autism spectrum
disorder (ASD) is a term used to describe a range of neurodevelopmental
disorders which are characterized by abnormal social interaction, communication
difficulties, stereotyped or repetitive behaviors, activities, and interests,
and in some cases, cognitive delays. The exact pathogenesis is unknown;
however, there is some evidence that brain inflammation plays a role in ASD and
several studies have found that children with ASD often have allergies. Immune
system mast cells are implicated in both allergic and
inflammatory reactions, are activated in autism, and the incidence of ASD is 10
times higher among children with mastocytosis (too many mast cells). The flavonoids
luteolin and quercetin have potent anti-inflammatory and antioxidant activities,
inhibit the release of inflammatory mediators from
mast cells, and reduce autism-like behavioral deficits in mice. The purpose of this
open-label study was to evaluate the safety and efficacy of a dietary
supplement containing luteolin and quercetin in children with ASD.
Fifty
children (42 boys and 8 girls, aged 4-10 years) with ASD based on clinical
assessments and scores on the Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) symptom
list and the Autism Diagnostic Observation Schedule diagnostic algorithm were
enrolled in the study conducted at Athens University "Attikon" 2nd
Psychiatric Clinic; Athens, Greece. Included children were medication and
luteolin naive. The exclusion criteria were as follows: having a medical condition
likely to cause ASD symptoms, having neurologic pathology above the brain stem (other
than uncomplicated nonfocal epilepsy), diagnosed with probable neonatal brain
damage, having mastocytosis, or a history of systemic inflammatory diseases.
The treatment was produced
in a Good Manufacturing Practices certified facility (Tishcon
Laboratories; Long Island, New York) under contract from Algonot, LLC
(Sarasota, Florida; www.algonot.com) specifically for the study. The 200 mg
capsules contained ˃95% pure luteolin and quercetin; 100 mg/capsule luteolin
from chamomile (Matricaria recutita) and
70 mg/capsule quercetin and 30 mg/capsule of the quercetin glycoside rutin,
both derived from Japanese sophora (Sophora
japonica) leaf. These flavonoids have poor oral absorption, so they were
formulated in microspheres by mixing them in olive (Olea europaea) kernel oil of low (˂0.01%) oleic acid and water
content. The dose was 1 capsule per 10 kg (22 lb) body weight/day taken with
food for 26 weeks.
The primary outcome
measures were the age-equivalent scores in the 3 domains of the Vineland
Adaptive Behavior Scales (VABS). The VABS is a validated parent interview tool
that assesses the child's actual functioning in real life, rather than specific
symptoms. Secondary outcome measures were the Aberrant Behavior Checklist
(ABC), the Autism Treatment Evaluation Checklist (ATEC), and the Clinical
Global Impression-Improvement score (CGI-I). Patients were evaluated at
baseline, 18 weeks, and 26 weeks. For the analysis, patients were divided into
2 age groups (4-6 years old, n = 25; and 7-10 years old, n = 25).
Forty patients (35
boys, 5 girls) completed the study. The withdrawals were due to increased
irritability (n=6, even though 2 were classified as good responders), poor
compliance (n=1), parent unable to administer the treatment (n=2), and parent declined
further participation after baseline (n=1). The patients received a mean of
7.75 hours/week of behavioral interventions, which did not change throughout
the study. It was noted "that 55% of
children had reported allergies or possible allergic symptoms."
At 26 weeks, there
were positive changes in the VABS age-equivalent scores, which were significant
for all domains (P < 0.01). The effect size was considered medium. All of
the gains in the communication, daily living skills, and social domains were
4.0-6.10% greater than what would be expected by maturation alone. Further
analysis of the age-equivalent scores indicated that only the initial adaptive function level influenced the final
results. "More-able children responded better to the study formulation,
whereas age, sex, and the presence of allergies were not good predictors for
the final outcome."
On
the secondary outcome measures evaluated with ABC, there was a large effect on
decreasing hyperactivity and a medium effect on improving noncompliance,
irritability and agitation, lethargy and social withdrawal, and stereotypic behavior
(P < 0.01 for all), compared with baseline. However, there was no
significant improvement on the ATEC except on the health/physical/behavioral
domain. The CGI-I parent scores indicated a minor improvement, although the primary
physicians rated 37.5% (15/40) children as much improved to very much improved.
On
the scales assessing behavioral difficulties, children with the worst baseline scores
on the ATEC speech/language/communication, ABC stereotypic, and ABC
hyperactivity domains had the greatest improvements with treatment. Parents
reported improvements in speech in 50%, better sociability in 48%, better
cooperation in 43%, better and prolonged concentration in 30%, improvement in
receptive language abilities in 30%, and better general communication intention
and abilities in 20% of the patients.
The
most frequent adverse event (AE) was increased irritability, which affected 54%
of patients for various durations. Irritability was usually transient, lasting
1 to 8 weeks in 66% of cases. In 74% of the cases, irritability started 2 to 7
days after treatment began. There were other, infrequently occurring AEs such
as sleeping difficulties and abdominal pain, but without a placebo control
group, the possible causal relationship between the AEs and the treatment could
not be evaluated.
In
summary, the treatment increased adaptive functioning and improved behavior. The
data suggest that the luteolin and quercetin combination would be more
beneficial for children who are higher functioning and have more behavioral
problems (stereotypies, hyperactivity, language, and communication problems). The
authors hypothesize that the irritability produced by the treatment may be
related to the phenol content, and report that a new product with lower phenol
content (NeuroProtek LP®; Algonot, LLC) has been developed.
The
findings are encouraging considering that the gains were beyond what could be
expected from a child's normal growth rate. However, it is unclear whether a
4-6% gain is clinically meaningful since there was no placebo control group and
the participants were not blinded. The study did not include follow-up tests to
evaluate whether the gains were long-lasting or acute. Another concern is that
>40% of the children were not able to swallow the capsules. The parents had
to open the capsules to sprinkle it on food, which could have altered the dose
actually consumed. This study needs to be repeated as a randomized,
placebo-controlled, double-blind study of the re-formulated low-phenol product
to evaluate if efficacy is maintained while reducing the AE of irritability.
—Heather S. Oliff,
PhD
|